NICE says yes to AstraZeneca's Iressa for NSCLC and Roche's Xeloda for gastric cancer.
This article was originally published in Scrip
NICE, the health technology appraisal body for England and Wales, says that it is now poised to recommend AstraZeneca's Iressa (gefitinib) for some NHS non-small cell lung cancer (NSCLC) patients after initially saying that it wanted more information. The firm has also managed to convince the institute that its patient access scheme would be of benefit.
You may also be interested in...
Canada has announced new restrictions on exports to help mitigate the impact of measures in the US to lower medicine prices there.
In the wake of the COVID-19 pandemic and the ensuing economic fallout, pharmaceutical companies could face a range of measures designed to cut government spending on medicines. From relaxing intellectual property rights to delaying reimbursement, In Vivo examines what might be in store for industry.
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.